Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,515 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline 0.9% Clear all
Active, not recruiting Phase 2 Interventional

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

NCT04323735
View directory record Official record
Conditions
Neurogenic Bladder
Interventions
Culturelle 10 Billion CFU Capsule
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2Phase 3 Interventional

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

NCT02427191
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
AmnioFix® Injectable, Saline Injection
Other · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 79 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Fresno, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

NCT02160574
View directory record Official record
Conditions
Surgical Site Infection
Interventions
ChloraPrep, 0.1% Sodium Lauryl Sulfate, 0.9% Physiological Saline, ZuraPrep without IPA
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Nebulized Hypertonic Saline for Bronchiolitis

NCT00619918
View directory record Official record
Conditions
Bronchiolitis
Interventions
Nebulized 3% saline, Nebulized 0.9% saline
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 24 Months
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2 Interventional

Study of NNZ-2566 in Patients With Traumatic Brain Injury

NCT00805818
View directory record Official record
Conditions
Brain Injuries
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 4 Interventional Results available

Effect of Steroid Injections in a Knee With Osteoarthritis

NCT01230424
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of NKTR-358 (LY3471851) in Healthy Participants

NCT04380324
View directory record Official record
Conditions
Healthy
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Not applicable Interventional Results available

Lidocaine Analgesia For Removal Of Wound Vac Dressings

NCT01126359
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo-Saline
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

NCT00780962
View directory record Official record
Conditions
Radiocontrast Nephropathy
Interventions
N-Acetylcysteine (NAC), 0.9% Sodium-chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 30, 2026, 11:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

HAT for the Treatment of Sepsis Associated With NASTI

NCT05157360
View directory record Official record
Conditions
Necrotizing Soft Tissue Infection, Sepsis
Interventions
HAT, Placebo
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

NCT01545570
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2376497, 0.9% sodium chloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 30, 2026, 11:33 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

NCT04531579
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 30, 2026, 11:33 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair

NCT03219580
View directory record Official record
Conditions
Brow Ptosis, Facial Scarring
Interventions
5-Fluorouracil, Normal Saline Flush, 0.9% Injectable Solution
Drug
Lead sponsor
Eyelid and Facial Consultants
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Houma, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 3 Interventional Results available

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

NCT03997383
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Placebo, Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

NCT01518985
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bendavia, Sterile saline (0.9%), Cigarette smoking
Drug · Other
Lead sponsor
Mighty Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Early Phase 1 Interventional Results available

Placental Lesions in Fetal Growth Restrictions

NCT04839185
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
Ferumoxytol infusion, MRI scan
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 30, 2026, 11:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

NCT07115017
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[18F] FZTA
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125
View directory record Official record
Conditions
Anthrax
Interventions
BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo)
Biological · Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 30, 2026, 11:33 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 11:33 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic Study for IV Allopregnanolone

NCT04468360
View directory record Official record
Conditions
Pharmacokinetic Study, Post Traumatic Stress Disorder
Interventions
PK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis, PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis.
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 11:33 AM EDT